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Purpose: Recently we identified high levels of expression of Eph-A6 in the macula of developing human retina and
showed localization of Eph-A6 to ganglion cells (GC). In the present study we investigated the expression of some members
of the ephrin family in developing primate retina, including the topography of Eph-A6 expression, and its ligands, in
developing macaque retinas.
Methods: We extracted RNA from human fetal retinas and probed for Eph-A5–A7, Eph-B1, ephrin-B2, and ephrin-A1-
A5 by RT–PCR, then prepared riboprobes for Eph-A5-A7, Eph-B1 and ephrin-A1, -A4 and -B2. Paraffin sections of fetal
macaque retinas were used to localize expression of Ephs and ephrins by in situ hybridization and immunohistochemistry.
Results: We identified prominent gradients of Eph-A6 mRNA expression in the ganglion cell layer (GCL) of fetal macaque
retinas of different ages. The gradient of Eph-A6 expression was high near the optic disc and low at the developing macula
at fetal day (Fd) 55. At Fd 70 and 80, the gradient of Eph-A6 expression was reversed, being higher temporal to the macula,
and low at the disc. By Fd 110, when the fovea begins to form, a pattern of expression was established that persisted into
the postnatal period, in which the highest levels of expression were detected at the developing fovea, and progressively
lower levels of expression were detected at increasing distance from the fovea. Beginning at Fd 70, we also detected a
gradient of Eph-A6 expression running perpendicular to the retinal surface within the GCL of central retina that was high
in the inner GCL and low in the outer GCL. This second pattern persisted into the neonatal period. We found the two
ligands for Eph-A6, ephrin-A1 and ephrin-A4, expressed by Pax2-immunoreactive astrocytes, in the optic nerve head and
in the retina, by in situ hybridization and immunohistochemistry. We propose that during development of the retinal
vasculature, migration of ligand-bearing astrocytes is slowed along this Eph-A6 expression gradient through repellent
Eph-A6 - ephrin-A1 and -A4 signaling.
Conclusions: Patterns of Eph-A6 expression in the developing macaque retina suggest that Eph-A6 - ephrin-A1 and -A4
repellent signaling has a role in retinal vascular patterning, and in the postnatal maintenance of projections from macular
and foveal GC.
The fovea centralis (fovea) is formed in temporal retina
during late fetal life by the centrifugal displacement of cells
of the inner retina, leaving cone cell bodies lining the floor of
the pit. The fovea is centrally placed in the less well defined
“macula.” The macula is a region approximately 3 mm in
diameter recognized clinically by its high concentration of
yellow, xanthophyll pigments (hence, macula lutea) and a
relative  absence  of  large  diameter  retinal  vessels.  In  this
region, the neural retina is also highly specialized: the density
of  all  neural  elements  is  elevated;  there  is  a  peak  spatial
density of cone photoreceptors; there are no rods; and there is
a prevalence of “midget” or “parvocellular’ circuitry [1-3].
Signals encoded by these circuits provide the brain with the
detailed  spatial  and  color  information,  characteristic  of
macular visual function. Absence of large retinal vessels from
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the macula is an adaptive advantage, since large vessels cause
“shadowing” of the cone mosaic [4] and if present, would
degrade the quality of the image that strikes the high density
cone array.
Under normal circumstances the foveal region is never
vascularized [5] and remains so throughout life. Despite this,
the principal retinal angiogenic factor, vascular endothelial
growth  factor  (VEGF),  is  highly  expressed  at  the  macula
during development of the retinal vessels [6,7], so it is a
paradox that macular vessels are slow to develop [8,9]. These
observations led us to the hypothesis that repellent guidance
cues  might  inhibit  the  migration  of  endothelial  cells,  and
astrocytes, into the macular region during development.
Three  lines  of  evidence  led  us  to  investigate  the
expression patterns of Eph receptors and their ligands. First,
Eph receptor signaling has an important role in retinal axon
pathfinding  [10-13]  and  retinal  vessels  follow  trajectories
similar  to  those  taken  by  retinal  axons  [14,15].  Second,
development of retinal vessels is dependent on Eph receptor
signaling  [16-19].  Third,  in  a  microarray  analysis  of
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2649differential gene expression in the developing human macula
[20], we found higher levels of expression of Eph-A6 in the
macula, confirmed by quantitative RT–PCR. In the present
study we aimed to identify the expression patterns of Eph-
A6 and its ligands in the developing macaque retina.
METHODS
Specimens: We used histological sections of retinas from 10
macaques at fetal days (Fd) 55, 64, 70, 80, 110, 115, 120, 145,
postnatal day (P) 5, and P 3 months. This developmental range
straddles the period during which the perifoveal capillaries
form and the foveal avascular area is defined, that is, between
about Fd 90 and several days postnatal [9]. The sections were
obtained by A.E. Hendrickson from the breeding colony of
the Primate Center at Bogor Agricultural University, (Bogor,
Indonesia), using protocols approved by the University of
Washington  (Seattle)  Animal  Care  Committee  and  in
compliance with guidelines of the Association for Research
in  Vision  and  Ophthalmology.  Fetuses  were  delivered  by
aseptic  caesarean  section,  euthanized  by  intraperitoneal
overdose  of  barbiturate,  and  then  enucleated.  Eyes  were
immediately injected with methyl Carnoy’s fixative, which
contains  a  6:3:1  ratio  of  methyl  alcohol:  acetic  acid:
chloroform. Specimens were then fixed whole by immersion
for  1–2  h,  as  described  previously  [21].  Sections  were
embedded in paraffin, and then 8 μm slices were cut. Only
sections passing through the optic disc and foveal region were
used for quantitative analysis in this study.
For RNA, four human retinas aged between 17 and 20
weeks of gestation (WG) were obtained at surgery to terminate
pregnancy, with informed maternal consent. Ethical approval
was  obtained  from  the  Human  Ethics  Committees  of  the
University of Sydney and The Australian National University.
Gestational age was determined by ultrasound before surgery
and confirmed by postmortem measurements of foot length.
RNA  was  extracted  from  donor  retinas  90–120  min
postmortem.  A  fifth  human  retina  of  13  WG,  the  period
immediately preceding appearance of vessels at the optic disc,
was  also  obtained  under  similar  circumstances  for
immunohistochemical analysis. This eye was fixed in 4%
paraformaldehyde, embedded in paraffin, and processed in the
same way as macaque eyes.
PCR and in situ hybridization: Consistent with a previous
study [21], we used RNA extracted from fetal human retinas
for  RT–PCR,  because  it  was  not  possible  to  obtain  fresh
macaque  retinas  for  RNA  extraction.  Whole  retinas  were
excised,  homogenized,  combined  with  Trizol  Reagent
(Invitrogen, Carlsbad, CA) and chloroform, then purified and
isolated  using  RNAqueous-Micro  RNA  isolation  kit
(Ambion, Inc., Austin, TX). In some cases, we used a 5 mm
trephine to obtain a biopsy of the developing macular region,
and extracted RNA from the macular sample as well as from
the remaining retina (“surround” sample). First-strand cDNA
synthesis was performed in a 20 μl reaction mixture using
1 μg RNA, 500 ng oligo (dT)18 primer, and 200 U SuperScript
III reverse transcriptase (Invitrogen). CDNA was probed for
expression of Eph-A5, -A6, -A7, -B1, and ephrins -A1, -A2, -
A3, -A4, -A5, and -B2, using primers shown in Table 1. PCR
products were visualized with electrophoresis using ethidium
bromide staining on a 1% agarose gel.
We  cloned  and  generated  digoxigenin  (DIG)-labeled
riboprobes from PCR products for Eph-A5, -A6, -B1, -A7 and
ephrin-A1,  -A4,  and  -B2.  Briefly,  cDNA  fragments  were
amplified from total RNA of human fetal retina, and cloned
using the pGEM-T DNA vector system and JM109 competent
cells  (#A3600;  Promega,  Madison,  WI).  The  plasmid
constructs  containing  the  DNA  fragments  were  purified,
sequenced, and linearized using Nco I, Not I, and Sac II
restriction enzymes (Promega). A DIG RNA Labeling Kit
SP6/T7  (#1175025;  Roche,  Basel,  Switzerland),  which
contains DIG-11-UTP, was used to transcribe the linearized
plasmid and produce the antisense and sense probes.
Paraffin sections of macaque retina were placed in xylene
(#XA003; Chem-Supply, Gillman, Australia) for 10 min for
dewaxing. They were rehydrated in graded ethanols (2×100%,
90%, 70%, and 50%) and rinsed in 0.9% NaCl then phosphate
buffered  saline  (PBS),  which  contained  0.8%  NaCl  in
phosphate buffer, pH 7.4. The sections were fixed in 10%
neutral buffered formalin (NBF; #90245; Merck, Darmstadt,
Germany)  for  20  min,  washed  in  PBS  (2×5  min),  then
immersed in 50 mM Tris–HCl, 5 mM EDTA (TE; pH 8.0)
containing 20 μg/ml of Proteinase K (#3115828; Roche) for
7 min at 37 °C. Following a rinse in PBS and re-fixation in
NBF for 20 min, the sections were immersed in a solution
containing 0.1 M triethanolamine (#T9534; pH 8.0; Sigma,
St. Louis, MO) and 2.5% acetic anhydride (#A6404; Sigma)
for 10 min. After a rinse in PBS then 0.9% NaCl, the slides
were dehydrated in graded ethanols and allowed to air dry.
Prior  to  hybridization,  coverslipped  sections  were
incubated for at least 1 h at 55 °C in prehybridization solution
that  comprised  the  following  ingredients:  50%  deionized
formamide, 20% dextran sulfate (#0198; Amresco, Solon,
OH), 500 µg/ml polyadenylic acid potassium salt (#P9403;
Sigma), 50 µg/ml yeast t-RNA (#R8759; Sigma), 50 mM
dithiothreitol  (#D9779;  Sigma);  and  a  salt  solution  that
contained 300 mM NaCl, 10 mM Tris base (#T6066; Sigma),
10 mM sodium phosphate (Na2HPO4; #S3264; Sigma), 5 mM
NaEDTA,  0.2%  Ficoll  400  (#F2637;  Sigma),  and  0.2%
polyvinylpyrrolidone  (#P5288;  Sigma).  For  hybridization,
each riboprobe was resuspended in hybridization solution at
about 250 ng/ml. The coverslip and prehybridization solution
was  carefully  removed  after  this  incubation  and  the
hybridization  solution  (prehybridization  buffer  containing
250 ng/ml riboprobe), heated to 55 °C, was applied to the
sections with a new coverslip. The riboprobes were allowed
to hybridize to the tissue overnight at 55 °C after which the
coverslips were removed and the sections rinsed in 4× saline
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and two washes of 0.1× SSC for 2 h at the optimal post-
hybridization wash temperature (60–65 °C). A final wash of
0.1× SSC at room temperature for 10 min was also applied.
The optimal post-hybridization wash temperature was that
which produced the least amount of background labeling. For
the Eph-A6 probes, the optimal hybridization temperature was
55 °C, with post-hybridization washes done at 65 °C. For
ephrin-A1  and  –A4,  optimal  hybridization  and  wash
temperatures were 55 °C and 62 °C, respectively.
The  slides  were  rinsed  in  washing  buffer,  which
contained  0.10  M  maleic  acid,  0.15  M  NaCl,  and  0.3%
Tween-20 (#0777; pH 7.5; Amresco). From there, they were
immersed in blocking reagent solution (#1096176; 10% w/v;
Roche) for 30 min. The sections were removed from the
blocking  solution  and  an  anti-DIG-alkaline  phosphatase
antibody (#1093274 Roche) diluted to 1:1,000 was applied to
the tissue and allowed to incubate for 30 min. The slides were
subsequently rinsed in washing buffer (3×40 min) then placed
for 5 min in a detection buffer that consisted of 100 mM Tris-
HCl,  100  mM  NaCl,  10  mM  MgCl2,  pH  8.0.  Following
hybridization  to  detect  Eph-A6  expression,  riboprobes
visualized by incubation for 5 min at room temperature in an
HNPP fluorescent detection set (#1758888; Roche) using a
Fast Red TR fluorescent substrate with a peak emission at 584
nm. The color reaction was stopped by washing in deionized
water for 10 min. Riboprobes detecting ephrin-A expression
were visualized by incubation in NBT/BCIP color substrate
(#1681451; Roche) for 16 h at 4 °C. A similar detection buffer
as  that  used  before  HNPP/Fast  Red  TR  fluorescent  color
detection was used except the MgCl2 was omitted. The color
reaction was stopped by washing in deionized water for 10
min, then preserved by fixing in NBF for 4 h at 4 °C. All
sections were mounted in glycerol, coverslipped, and sealed
with  fingernail  polish.  The  sections  were  scanned
immediately or stored at −20 °C and scanned within 24 h (Fast
Red)  or  48  h  (NBT/BCIP)  after  completion  of  the  color
reaction.
Immunolabeling: Double immunolabeling using antibodies to
ephrin-A1 and -A4 with anti-paired box-2 (Pax2) was used to
localize ephrin proteins in the retina. Nonimmune goat IgG
was used as a control for ephrin immunoreactivity. A list of
antibodies  used  and  their  dilutions  is  shown  in  Table  2.
Briefly, sections were dewaxed in xylene for 10 min and
rehydrated  in  graded  ethanols  (2×100%,  90%,  70%,  and
50%),  then  rinsed  in  deionized  water  followed  by  0.3%
Revealit-Ag  (#AR1002;  ImmunoSolution,  Newcastle,
Australia) in PBS (PBSR). The sections were then incubated
in Revealit-Ag for 1 h at 37 °C for antigen retrieval and
subsequently  washed  in  PBSR  for  5  min.  Sections  were
blocked in 10% serum (diluted in PBSR) for 1 h at 37 °C, and
incubated in primary antibody overnight at 4 °C. To avoid
cross-reactivity,  we  applied  primary  antibodies  raised  in
different species to the tissue consecutively. After thorough
TABLE 1. PCR PRIMERS.
Entrez Gene ID Gene Primers (5′-3′)
2044 Eph-A5 F: ACCGATGAACCTCCCAAAAT
R: TAGCCTGCTGCTGTACGTG
285220 Eph-A6 F: TGGGATGCCATCACTGAAAT
R: CAAGAGGAACCAGCCAATCT
2045 Eph-A7 F: GATCCCAGAGGCTCTTTGC
R: TTGATGGACAGCTCTATTTGG
2047 Eph-B1 F: AGCTGCTCCCGCTGTGAC
R: TGCTCCGATGACCTCTTCA
1942 ephrin-A1 F: TCCGGAATGAGGACTACACC
R: AGTGCCTGTCCCTCTCTTCA
1943 ephrin-A2 F: GCTGCTGCTCCTGCTGTTAC
R: CTCGCCGTTGACCATGTA
1944 ephrin-A3 F: CCTGCACTGGAAGTGTCTGA
R: ACCAGGAGTCAGGGAAAGGT
1945 ephrin-A4 F: TGGAGAGAGTGGCACATCAG
R: GGAGGGCAACAAAAAGATGA
1946 ephrin-A5 F: GATGTGTGTGTTCAGCCAGG
R: AGGGAGGCAGGAACAAGTTT
1948 ephrin-B2 F: TAACCAGGAGGGAGGGGTGT
R: GCCGAATGCTACAAGACTAGG
PCR of several A-class Ephs and ephrins as well as Eph-B1 and ephrin-B2   was run using cDNA from four fetal human retinas
of 17–20 WG. The PCR products for Eph-A5, -A6, -A7, -B1 and ephrin-A1, -A4, and -B2 were then used to generate DIG-labeled
riboprobes for in situ hybridization.
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2651rinsing, ephrin (and control goat IgG) binding was visualized
following  1.5  h  incubation  in  a  biotinylated  secondary
antibody then 1.5 h incubation in streptavidin Alexa 488.
Pax2 binding was visualized using Alexa 594 conjugated to
an anti-rabbit secondary antibody (4 h incubation). Secondary
antibodies and labels were allowed to incubate at 37 °C, and
all antibodies were diluted in PBSR. Sections were rinsed in
PBSR for 2×5 min after each incubation to remove unbound
antibodies.
In  some  cases  immunohistochemistry  to  detect  Pax2
expression was performed post-hybridization for ephrin-A1
and -A4. After a PBS wash (2×5 min), the ephrin-A in situ
hybridization (ISH) sections were blocked in 10% normal
goat serum for 30 min and incubated with anti-Pax2 double
label overnight at 4 °C. Pax2 labeling was visualized with 1
h incubation in a biotinylated secondary antibody followed by
30 min incubation in streptavidin Alexa 488. The serum and
antibodies  were  diluted  in  PBS,  and  the  blocking  and
secondary antibodies were allowed to incubate with the tissue
at room temperature. The sections were washed in PBS for 5
min after each incubation period. All sections subjected to
immunohistochemistry  were  mounted  as  per  the  in  situ
hybridization protocol.
Imaging  and  optical  densitometry:  Sections  were  imaged
using a Zeiss LSM 5 Pascal confocal microscope system and
Pascal version 4.0 software (Jena, Germany). The microscope
was equipped with LASOS HeNe 543 nm and Argon 488 nm
scanning lasers (Jena, Germany). Hybridized sections were
viewed within 24 h to avoid errors due to spread of the color
reaction product.
Image collection: For montages, we used a 20× objective and
scanned a field size of 450×340 µm using standardized laser
settings and optical sectioning. The full resolution images
were  exported,  converted  to  grayscale  for  optical
densitometry,  and  assembled  as  a  montage  using  Adobe
Photoshop (version 10.0.1). For immunolabeling, different
objective lenses (20× or 40×), scan field sizes and optical
section stack sizes were used according to the distribution of
labeling. For optical densitometry we used a 40× objective
and  a  frame  size  of  1024×1024  pixels,  sampling  a  field
210×210 μm, and optical sectioning at a constant interval of
0.4 µm to create an image stack of 3.5 µm thickness. Z-
sections were merged using the “projection” feature on the
Pascal software. Settings for laser transmission, scan speed
and  direction,  signal  averaging,  pinhole  size,  and  optimal
detector  and  amplifier  gains  were  held  constant  during
collection of all images from a single labeled section so that
valid comparisons of labeling intensity could be performed.
For printed viewing, the immuno images and images used for
optical densitometry analysis were compiled in Photoshop in
CMYK  format  and  adjusted  for  optimal  brightness  and
contrast.
Optical densitometry: Quantitative analyses were performed
on  five  sample  regions  temporal  to  the  optic  disc  [21]:
immediately adjacent to the optic disc (OD); nasal to the
macula  (nasal),  at  the  mid-point  between  the  OD  and
developing fovea; on the nasal foveal rim (rim); in the center
of the foveal cone mosaic (fovea); and temporal to the fovea
(temporal), such that the nasal and temporal samples were
approximately  equidistant  from  the  fovea.  Optical
densitometry was performed using ImageJ (version 1.38x;
National  Institutes  of  Health,  Rockville,  MD)  on
representative  sections  from  one  specimen  at  each
developmental age.
TABLE 2. ANTIBODIES AND IMMUNOREAGENTS.
Antibody Dilution Manufacturer
Primary antibodies
Anti-mouse ephrin-A1 (goat, poly) 1:2,500** R&D Systems
Anti-human ephrin-A4 (goat, poly) 1:2,500** R&D Systems
Anti Paired Box-2 (Pax2; rabbit, poly)* 1:100 Covance
Control antibody
Normal goat IgG 1:25,000** R&D Systems
Secondary antibodies
Biotinylated horse anti-goat (0.3% PBSR) 1:200 Zymed
Biotinylated goat anti-rabbit (0.3% PBSR) 1:200 Zymed
Visualization
Conjugated goat anti-rabbit Alexa 594 (0.3% PBSR) 1:1,000 Invitrogen
Streptavidin Alexa 488 1:1,000 Invitrogen
Antibodies raised against the two ligands to Eph-A6, ephrin-A1,   and -A4, were used to localize these proteins in sections of fetal
macaque retina. Anti-Pax2  double immunolabel was used to localize immature astrocytes, while background labeling was
visualized using normal goat IgG antibody. *Pax2 is cross-reactive to human and other species. **IgG concentration applied to
tissue is equal to ephrin antibodies given the reconstituted antibodies stocks were 0.1 mg/ml for ephrins and 1 mg/ml for IgG.
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2652Profiles of Eph-A6 expression: Images from the five locations
in each retina were converted to grayscale, and optical density
profiles  of  DIG-labeled  mRNA  were  extracted  using  the
rectangular selection tool (in ImageJ). To construct profiles
showing Eph-A6 expression across the full thickness of the
retina, we inverted images so that the most intense labeling
appears black. Where the fovea had not formed (younger than
115 days) the profiles show the average pixel intensity in each
line  of  pixels  parallel  to  the  retinal  surface.  For  older
specimens with a fovea, the profile was constructed from a
narrow sample area centered on the base of the pit. To control
for  background  labeling  of  the  antisense  riboprobe,  we
calculated the final intensity data (displayed on the profile) as
a ratio against the intensity of the labeling in the ganglion cell
layer (GCL) of the control (sense probe) sections of the same
specimen.  The  Mann–Whitney  test  was  used  to  compare
labeling intensity in inner and outer halves of the GCL, at
fovea and rim locations.
Labeling intensity in the GCL at different locations in a single
specimen:  We  used  optical  densitometry  to  quantify  the
intensity of mRNA labeling in the GCL at different locations
in each specimen, to characterize the observable expression
gradients.  In  all  samples,  cell  nuclei  were  not  labeled  (0
intensity). The range of pixel intensities in the cytoplasm
(where mRNA is expressed) ranged from very low levels up
to saturation. A histogram displaying the range and frequency
of  pixel  intensities  throughout  each  sample  location  was
obtained using ImageJ, and the mode intensity was identified.
Because  we  aimed  to  obtain  objective  measures  of
brightness in the mRNA labeling intensity (a parameter of
mRNA  expression)  to  identify  locations  with  the  highest
levels of Eph-A6 expression, we discarded pixel values falling
below the mode. We compiled images of the full thickness of
the GCL at each of the five sample locations from successfully
hybridized sections. We then used ImageJ to extract the mean
intensity of the remaining pixels in each line of an image of
the GCL (one data point per line of pixels), in each sample
location. This approach did not alter the relative mean levels
of brightness between samples, only the standard deviations
of the means. The Mann–Whitney test was used to compare
mean pixel intensity values in the foveal and nasal locations
in each section analyzed.
RESULTS
RT–PCR and in situ hybridization: We detected expression of
Eph-A5, -A6, -A7 and -B1, and ephrin-A1, -A3, -A4, and -B2
in  cDNA  from  human  fetal  retinas  (Figure  1).  In  situ
hybridization showed expression of Eph-A5 (data not shown)
and -A6 in the cellular layers of the retina, particularly the
GCL. We did not obtain reliable results for Eph-B1 or ephrin-
B2.  Although  Eph-A7  was  detected  by  RT–PCR,  Eph-A7
mRNA was not visualized in the retina, similar to previous
findings [22]. In contrast with a previous study [22], we did
not detect ephrin-A5 by RT–PCR. Ephrin-A5 is expressed in
peripheral retina and ciliary processes of the retina [22], which
may have been deficient in the samples used for RT–PCR in
the present study.
Eph-A6 expression: We detected Eph-A6 mRNA expression
in the cell layers of fetal macaque retinas (Figure 2). Unlike
the other family members tested, the pattern of labeling for
Eph-A6 mRNA in the GCL varied as a function of both age
and  retinal  location.  This  is  illustrated  in  Figure  3  by
comparing labeling patterns at three locations (fovea, rim, and
nasal), at four different ages. At Fd 55 (Figure 3A-C) Eph-
A6 mRNA was found at low levels in the cellular layers, with
the lowest levels detected in the middle of the inner nuclear
layer, and the highest levels detected in the outer nuclear layer.
By Fd 80 (Figure 3D-F) Eph-A6 expression was much higher
in the GCL than other layers, but low in the nasal location
compared  with  fovea  and  rim,  suggesting  a  gradient  of
expression across the retinal surface, centered on the fovea.
By  Fd  110,  a  strong,  fovea-centered,  gradient  of  Eph-A6
expression was detected across the GCL such that Eph-A6
expression  was  highest  in  the  foveal  GCL  (Figure  3G),
intermediate in the GCL on the foveal rim (Figure 3H) and
lower in the nasal GCL (Figure 3J).
A  second  gradient  of  Eph-A6  expression,  running
perpendicular to the retinal surface, was also detected in the
GCL at fovea and rim locations at Fd 80 and Fd 110. At these
ages Eph-A6 expression is highest in the ganglion cells (GC)
closest to the retinal surface, and considerably lower in GC
adjacent to the inner plexiform layer. These gradients of Eph-
A6 expression were still distinct on the foveal rim at Fd 145
(Figure 3L), and are explored in greater detail as follows.
Inner-to-outer GCL gradient of Eph-A6 expression: Optical
densitometry profiles of Eph-A6 mRNA showed a gradient of
Eph-A6 mRNA expression across the depth of the GCL at
Fd 80, 110, and 145 at fovea and rim locations (Figure 3 D-
E,G-H,K-L), and are indicated in the densitometry profiles by
asterisks (*). Highest levels of expression were detected in the
inner GCL, and typically, the levels of Eph-A6 mRNA in the
outer GCL were approximately half that detected at the inner
GCL margin. Labeling was generally low in the nerve fiber
layer. This effect was also detected in the rim samples from
specimens at P 5 days and P 3 months (data not shown).
In a specimen at Fd 115, when the perifoveal capillary
plexus was becoming established around the foveal avascular
zone, this gradient of Eph-A6 expression was particularly
prominent (Figure 4). In this retina there was a clear peak in
Eph-A6 mRNA expression in the inner GCL in the foveal
avascular area, in which the fovea was beginning to form. On
the margin of the foveal avascular area, which ultimately
becomes the foveal rim, the gradient of high inner GCL and
lower  outer  GCL  expression  of  Eph-A6  mRNA  was  also
prominent. Capillaries that formed the perifoveal plexus were
present deep in the GCL (arrows, Figure 4A). Less than a
millimeter farther into temporal retina (Figure 4B) both the
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2653distribution of Eph-A6 in the GCL and the placement of the
blood vessels were quite different, such that Eph-A6 levels in
the GCL were somewhat lower than at the fovea and more
uniform across the GCL. At this location the retinal vessels
were  also  more  superficially  placed  in  the  GCL  (arrows,
Figure 4B).
Eph-A6 expression varies with eccentricity: The histograms
in Figure 5 summarize the mean brightness of Eph-A6 mRNA
labeling in the GCL, at five sample locations, in eight retinas.
The data showed a gradual change in the distribution of Eph-
A6 across the five locations between Fd 55 and P 3 m. At
Fd 55, the highest levels of Eph-A6 expression were detected
between the fovea and optic disc (nasal), and the lowest levels
were  detected  temporal  to  the  fovea  (temporal),  with
intermediate levels of expression at the fovea and on the rim.
By Fd 70, the highest levels of Eph-A6 were detected in the
temporal sample, and the lowest levels near the OD. However,
by  Fd  110,  when  the  fovea  was  forming  and  the  foveal
avascular  area  was  being  defined,  a  pattern  of  Eph-A6
expression emerged that persisted into the postnatal period.
That is, the highest levels of Eph-A6 mRNA were detected in
the GCL at the fovea, and there were lower levels of Eph-A6
in the GCL temporal and nasal to the fovea (Figure 5; Fd 110,
Fd 120, Fd 145, P 5 days and P 3 m). Thus, there was a gradient
of Eph-A6 expression in the GCL, in which peak expression
occurred  in  the  emerging  fovea.  The  morphological
appearance of this gradient of Eph-A6 mRNA labeling is
illustrated in Figure 4 (Fd 115), which is representative of the
pattern of mRNA labeling seen in all specimens in this age
range.  As  shown  in  Figure  4,  by  approximately  3  mm
eccentricity (right hand side of Figure 4B), Eph-A6 expression
in  the  GCL  was  at  very  low  levels,  comparable  with  the
remainder of the GCL. Eph-A6 expression in the GCL was
uniform and at low levels outside the analyzed region.
Ephrin-A1 and -A4 localization: Using RT–PCR, we detected
three ephrin-A ligands in the retina: A1, A3 and A4 (Figure
1B). Cells expressing the ligands of Eph-A6 - ephrin-A1 and
ephrin-A4 [23] were identified in fetal primate retina using in
situ hybridization and immunolabeling (Figure 6). Limited
tissue  resources,  combined  with  difficulties  localizing
astrocytes in the GCL of hybridized sections due to their small
size and sparse distribution, prevented a detailed analysis of
these cells in the vicinity of the developing fovea. Rather we
focused on the optic nerve head, where astrocytes are found
at higher densities, and in a relatively cell-sparse environment,
compared with the retina.
Ephrin-A1 and -A4 mRNA was identified in cells in the
optic nerve head in a 13 WG human retina (Figure 6A,E,G).
These cells were distributed throughout the proximal optic
nerve and optic nerve head, showing some encroachment into
the  adjacent  nerve  fiber  layer  (NFL).  Counter-
immunolabeling  with  antibody  against  Pax2  showed
Figure 1. RT–PCR analysis of Eph and
ephrin expression in 20 WG fetal human
retina.  A:  We  found  low  levels  of
amplification  of  Eph-A5,  and  (B)  no
amplification of ephrin-A2 and -A5. Eph
and ephrin PCR primers are listed in
Table 1. PCR products were visualized
with  electrophoresis  using  ethidium
bromide staining on a 1% agarose gel,
and  used  to  generate  DIG  labeled
riboprobes for Eph-A5, -A6, -B1, -A7,
and ephrin-A1, -A4, and -B2.
Molecular Vision 2009; 15:2649-2662 <http://www.molvis.org/molvis/v15/a282> © 2009 Molecular Vision
2654colocalization of mRNA and Pax2 in these cells, indicative of
immature or migrating astrocytes [24]. The dark field image
(Figure  6A)  shows  the  distribution  of  ephrin-A1  mRNA-
containing cells (small arrows) in the optic nerve head and
adjacent  retina.  A  triangular-shaped  cluster  of  ephrin-A1
expressing cells can also be seen adjacent to the optic nerve
head, at the optic nerve-retinal boundary (Figure 6A, heavy
arrows). The inset to the left shows this region in bright-field
illumination. The inset to the right shows colocalization of
Pax2 (green) and ephrin-A1 (white) on the margin of the optic
nerve head and Bergmeister's papilla (white box). A similar
pattern of expression was observed for ephrin-A4, which also
colocalized  with  Pax2  (Figure  6E-G).  The  sense  probes
showed no specific labeling (Figure 6A far right inset, Figure
6H).
We also detected moderate immunoreactivity for ephrin-
A1 and -A4 in the optic nerve head and in the retinal ventricular
zone adjacent to the optic nerve head, and in Bergmeister’s
papilla in fetal macaque retinas at Fd 55 (Figure 6B-D, K-M),
Fd 64, and Fd 70 (not shown). These ephrin-A1 and -A4-
immunoreactive cells were also immunoreactive for Pax2,
although some Pax2-immunoreactive cells did not express
these ephrins. Specimens incubated in nonimmune IgG of the
same class as the ephrin-A antibodies showed no labeling
(Figure 6J).
DISCUSSION
In humans, macaques, and marmosets, the retinal vasculature
develops relatively late, starting at around 14 WG in humans,
Fd 70 in macaques and Fd 100 in marmosets. On the nasal
side of the optic disc, vessels grow in a radial fashion toward
the periphery, similar to the pattern of growth seen in rodent
models. However, temporal to the optic disc the developing
vessels avoid the macular region, which they skirt around in
their trajectory toward the periphery [25-31], and growth of
vessels along the horizontal meridian, and in the vicinity of
the  fovea  is  very  slow  [8,9].  While  the  macula  is
developmentally  the  most  advanced  region  of  the  neural
retina, during the early phase of vascular outgrowth it remains
avascular for a prolonged period, so that completion of the
capillary plexus that surrounds the fovea is delayed into the
neonatal period in humans and monkeys (reviewed in [7,31]).
The factors responsible for the delayed development of the
perifoveal capillaries have not been identified. The present
results show gradients of mRNA expression for the axon
Figure 2. Eph-A6 expression in Fd 110
macaque retina (foveal region) revealed
by in situ hybridization. A: Antisense
riboprobe strongly labeled the ganglion
cell  layer  (GCL),  particularly  the
innermost  portion.  B:  Sense  probe
produced no specific labeling. Confocal
gain and offset settings were the same in
A and B. Abbreviations: inner nuclear
layer (INL); inner plexiform layer (IPL);
outer  nuclear  layer  (ONL);  outer
plexiform layer (OPL).
Molecular Vision 2009; 15:2649-2662 <http://www.molvis.org/molvis/v15/a282> © 2009 Molecular Vision
2655guidance receptor Eph-A6 in the GCL of macaque retina that
coincide with key phases of retinal vascular development. We
also find by in situ hybridization and immunohistochemistry
the two ligands for Eph-A6, ephrin-A1 and -A4, on Pax2-
positive cells in the optic nerve head and nerve fiber layer
consistent with the identification of astrocytes, which lead the
developing vessels into the retina. These results implicate
Eph-A6 in vascular development in the primate macula.
We  also  detect  high  levels  of  Eph-A6  expression  in
macular GC well into the postnatal period, after development
of  the  retinal  vasculature  is  completed.  Eph-A6  has  been
implicated in the prenatal guidance of axons to target nuclei
during human development [22], and it has been suggested
previously  that  these  synaptic  territories  are  “refined”
postnatally [32]. We suggest that during postnatal refinement
of synaptic territories, high levels of Eph-A6 expression in
macula may serve to “mark” GC that convey signals from the
foveal region to the visual target nuclei.
Eph receptor signaling: Eph tyrosine kinase receptors are
divided into A and B classes according to the nature of the
ephrin ligands they bind. Both classes of ligand-receptor pairs
participate in chemoattractant and chemorepellent signaling,
in either a forward direction–i.e., downstream signaling in the
receptor-bearing cell–or in reverse, in which interactions with
the receptor initiate changes upstream, in the ligand-bearing
cell,  directing  cell  movement,  adhesion,  and  de-adhesion
events.  Repellent  signaling  along  opposing  gradients  of
ligands  and  receptors  of  both  classes  is  the  principal
mechanism underpinning topographic mapping of the retina
onto visual target nuclei, in a variety of species [10,33-39],
including humans [22]. For comprehensive reviews, see [13,
40,41].
Graded Eph-A expression has been described in many
regions of the developing vertebrate central nervous system,
including retina [22,35,36], superior colliculus [35,42,43],
dorsal lateral geniculate nucleus [22,39,44,45], and cortex
[46-48]. These and other studies show that accurate mapping
of  projections  onto  sensory  centers  depends  on
complementary  gradients  of  ligands  and  receptors,
particularly  Ephs  and  ephrins,  along  with  other  factors
including coordinated firing of cohorts of projecting neurons
[39,49-51].  In  addition,  Eph  receptors  and  ephrins  are
implicated in angiogenesis and vascular remodeling. Eph-B
signaling has a role in arteriovenous differentiation in vitro,
and vascular development in the periphery in vivo. B-class
ligands  and  receptors  have  been  identified  in  the  central
nervous system and retina [17,18], peripheral ganglia and
nerves (reviewed in [52]). Ephrin-B2, expressed by arterial
endothelial cells, interacts with Eph-B4, expressed by venous
endothelial  cells,  resulting  in  bidirectional  signaling  that
inhibits VEGF- and angiopoietin-1-induced endothelial cell
proliferation  and  migration  [52-55].  Different  roles  in
Figure 3. Optical densitometry profiles
of Eph-A6 mRNA expression. A-C: At
Fd 55, Eph-A6 is expressed in all cell
layers  at  each  location,  but  at  higher
levels in the outer nuclear layer (ONL)
compared to other layers. D-F: By Fd
80,  Eph-A6  mRNA  is  higher  in  the
ganglion  cell  layer  (GCL)  than  other
layers. The mRNA is also higher at the
fovea  and  rim  locations  compared  to
nasal (F). At the fovea (D) and rim (E)
locations there is a gradient of Eph-A6
mRNA in the GCL, with significantly
higher levels of mRNA labeling present
in the inner GCL, and lower levels in the
outer GCL (*p<0.0001, Mann–Whitney
test). G-J: A similar gradient of mRNA
expression was detected in the fovea and
rim locations in a Fd 110 retina. K-L:
Eph-A6  mRNA  expression  remains
relatively high in the GCL at Fd 145 at
the fovea (K) and on the rim (L), where
an inner-to-outer gradient of expression
in  the  GCL  is  still  detected.  Eph-A6
expression  is  relatively  lower  and
uniform  nasal  to  the  fovea  (M).
Abbreviations:  inner  nuclear  layer
(INL); inner plexiform layer (IPL).
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2656vascular development have been identified for A-class ephrins
and their receptors. Ephrin-A1 is expressed at sites of vascular
development during mouse embryogenesis [56] and acts as a
chemoattractant for endothelial cells in vitro following an
inflammatory signal [57].
Significance of graded Eph-A6 expression in primate retina:
A role in vascular patterning?—The most prominent
gradient  of  Eph-A6  expression  occurs  as  a  function  of
eccentricity from the developing fovea, such that peak Eph-
A6 expression occurs at the fovea (0 eccentricity), with a
gradual decline in expression with increasing eccentricity, out
to about 3 mm. A second gradient runs perpendicular to the
retinal surface and is confined to the GCL of the foveal region
and  immediately  adjacent  retina  (to  about  1.5  mm
eccentricity). These gradients begin to emerge at about Fd 80,
after retinal vessels have emerged from the optic disc, and
during the period when there is slow growth of retinal vessels
along the horizontal meridian [9] and in the macular region
[8].
Prior to Fd 80 our data suggest that expression patterns
of Eph-A6 are quite different. At Fd 55, when the foveal region
has just begun to differentiate, Eph-A6 expression is higher
near the optic disc than at the incipient fovea (Figure 5),
consistent  with  a  previous  study  of  human  retina  at  a
comparable stage of development [22]. High expression of
Eph-A6 at the disc would inhibit migration of ligand-bearing
astrocytes into the retina, resulting in their accumulation in
the optic nerve head as well as in Bergmeister's papilla, which
is invested in astrocytes [58] that express ephrin-A1 and -A4
(data not shown). At Fd 70 we find a relative drop in levels of
Eph-A6  expression  at  the  optic  disc  (Figure  5).  This
corresponds with the earliest stages of retinal vessel formation
in  the  macaque  [28,31];  this  relative  decline  in  Eph-A6
expression may be permissive to astrocytes entering the retina
at this stage. However, because we have limited numbers of
specimens in this early age range, these results require further
clarification and confirmation.
Our most significant findings are from five animals, aged
between  Fd  110  and  P5,  during  which  period  the  foveal
avascular region is defined, and the foveal depression forms
[9,31,59]. During this phase we find a distinct peak of Eph-
A6 expression at the developing fovea (Figure 4 and Figure
5), with expression falling to lower levels either side of the
fovea. Early in this period (Fd 105–120) the foveal avascular
area is defined in the GCL, apparently by the migration of
astrocytes being brought to a sudden halt on the edge of a ”no-
go” zone that defines the fovea [9]. Our present findings
suggest that high levels of Eph-A6 expression in the GCL of
Figure 4. In situ hybridization for Eph-A6 expression in a Fd 115 macaque retina. A: At the developing fovea and in adjacent temporal retina,
peak Eph-A6 mRNA expression is detected in the inner ganglion cell layer (GCL) within the foveal avascular area (bracket). Large arrows
mark vessels at the inner margin of the perifoveal plexus. The area between the two large arrows is devoid of vessels. Smaller arrows indicate
vessel profiles deep in the GCL (GCL plexus), which is a characteristic of macular vessels. B: Approximately 500 µm further into temporal
retina, vessels (arrows) are present in the inner and outer GCL, and levels of Eph-A6 mRNA in the GCL are lower, and more uniform across
the depth of the GCL, compared with A. Together, the images show two gradients of Eph-A6 expression: a high-to-low gradient from inner
to outer GCL at the developing fovea (in A), and a high-to-low gradient from fovea to periphery (top left GCL in A to lower right GCL in
B). Both A and B are at the same magnification. Abbreviations: inner nuclear layer (INL); outer nuclear layer (ONL).
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2657the  developing  foveal  region  may  have  roles  in  driving
capillaries deep into the GCL, and defining the no-go zone,
by repelling ligand-bearing astrocytes. Further, these high
levels  of  Eph-A6  expression  may  explain  the  previously
documented egress of astrocytes from the foveal region in the
prenatal phase of monkey retinal development [9,60,61].
A distinctive feature of the perifoveal capillaries is their
position  in  relation  to  the  laminae  of  the  neural  retina.
Throughout most of the primate retina, the innermost layer of
vessels is found at the GCL-NFL interface. In the macula the
innermost layer of capillaries forms at the GCL-IPL interface
(Figure 4) [9,27,31], rather than more superficially at the
GCL-NFL interface as in the rest of the retina. There are no
known  cues  to  explain  the  deep  positioning  of  macular
capillaries in the GCL. We propose that the Eph-A6 gradient
identified in the present study, which runs perpendicular to
Figure  5.  Mean  optical  densitometry
measures of Eph-A6 mRNA expression
in the ganglion cell layer. Densitometry
was performed at five sample locations
(schematic) in eight retinas of different
ages  (one  section  quantified  at  each
age). Note that the levels of expression
(y-axis) are in arbitrary units, and not
directly  comparable  between  animals.
The data show that the relative levels of
Eph-A6  at  the  five  sample  locations
change between Fd 55 and Fd 80, but
that by Fd 110 a pattern of expression is
established where peak levels of Eph-
A6 mRNA are detected in the ganglion
cell layer (GCL) at the fovea. There is a
gradual decline in expression levels at
locations increasingly distant from the
fovea. Levels of mean Eph-A6 optical
densitometry  measures  were
significantly  different  between  foveal
and nasal locations at all ages (Mann–
Whitney, p<0.0001), where n=number
of lines of pixels of the image analyzed
(see  Methods).  Note  that  the  Fd  55
section did not pass through the optic
disc (OD).
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2658Figure 6. Localization of ephrin-A1 (A-D) and -A4 (E-H, K-M) in human and macaque retinas. A: Low magnification, dark field image of a
section from a 13 WG human retina showing ephrin-A1 mRNA expression (white) in cells distributed throughout the optic nerve head and
immediately adjacent retina. The yellow box indicates the region shown in bright-field illumination (left inset). A triangular cluster of cells
expressing ephrin-A1 mRNA in the outer neuroblastic layer of the retina, adjacent to the optic nerve is denoted by a heavy arrow. These cells
were also immunoreactive for Pax2 (see F and G). Ephrin-A1 expressing cells in the optic nerve head and adjacent to Bergmeister's papilla
are indicated by the white box. The inset to the right shows colocalization of ephrin-A1 (white) and Pax2 (green) in these cells. The far right
inset shows cells in the same regions of the adjacent sense-treated section. B-D: High magnification image of the optic nerve in a Fd 55
macaque shows ephrin-A1 immunoreactivity (green) on the plasma membrane of cells (arrows) whose nuclei were Pax2 immunoreactive
(red),  indicating  the  cells  are  astrocytes.  Inset  in  D  shows  a  high  magnification  view  of  an  astrocyte  with  punctate-like  ephrin-A1
immunolabeling on its plasma membrane. E-G: Dark field scan of the optic nerve head showing ephrin-A4 mRNA expression (white) in
Pax2-positive astrocytic cells (green) in the 13 WG human retina. H: The ephrin-A4 sense probe showed no specific labeling in a similar field
in the optic nerve head. J: Goat IgG, control serum for ephrin-A1 and -A4 (Alexa 488), did not label astrocytes in Fd 55 tissue. K: At Fd 55,
ephrin-A4 immunoreactivity (green) was detected in the optic nerve head (ONH) and adjacent retina. L-M: Double labeling with anti-Pax2
(red) shows ephrin-A4 immunoreactivity surrounding the Pax2 immunoreactive nuclei, indicating they are astrocytes (arrowheads). Astrocytes
in the outer neuroblastic layer at the retina-optic nerve junction are Pax2 immunoreactive (large arrow), and cells on the outer margin of this
population are also ephrin-A4 immunoreactive. Scale bars in A represent 50 µm. Scale bars in panels B-M represent 25 µm. Abbreviations:
antisense (AS); ganglion cell layer (GCL); immunoreactivity (IR); nerve fiber layer (NFL); outer neuroblastic layer (ONB); optic nerve head
(ONH).
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2659the retinal surface in the macular region, may explain the deep
positioning of the macular capillaries. That is, we suggest that
the high level of Eph-A6 in the innermost cells of the GCL
repels the migrating astrocytes into the deeper layers, where
levels of Eph-A6 mRNA are much lower. While the present
data  provide  a  sound  basis  for  modeling  the  cellular
interactions between GC and astrocytes that help to define the
foveal avascular area, further in vitro studies are needed to
validate and strengthen these hypotheses.
A role in mapping macular ganglion cell projections?:
The Eph–ephrin-A family has a key role in the mapping of
GC projections onto the target visual nuclei [11,13], and it has
been argued that the pattern of expression of the Eph–ephrin-
A  genes  in  the  human  retina  may  also  contribute  to  the
formation and maintenance of eye-specific projections to the
laminae of the dorsal lateral geniculate nucleus [22]. Mapping
of GC axons into broad territories in the visual targets takes
place in macaques in the prenatal period [62]. While relatively
little data are available concerning the postnatal period of GC
axon-projection refinement in primates, it appears that this
period of plasticity, during which preservation of synaptic
territory of macular and foveal GC would be a priority, lasts
until several months postnatal [32]. The sustained, high levels
of  expression  of  Eph-A6  by  macular  GC  in  the  postnatal
period, described here, indicates that expression of Eph-A6
may  mark  the  projection  from  central  retina  during  the
postnatal phase of synaptic remodeling in the target visual
nuclei.  Such  a  role  would  predict  reciprocal  gradients  of
expression in the visual targets of the ligands ephrin-A1 and
-A4. We aim to undertake these experiments in the near future.
Consistent with this, a role for Eph-A6 in the axon projection
to  visual  cortex  has  also  been  proposed,  with  Eph-A6
expression localized to the site of visual cortex development
in the macaque brain [63] before the arrival of thalamocortical
projections [64].
Conclusion:  The  present  data  implicates  Eph-A6
signaling in the development of retinal vessels prenatally, and
suggests  a  role  for  Eph-A6  in  the  preservation  and
maintenance of projections from macular and foveal GC, in
the late prenatal and postnatal phase of development. In vitro
analysis  of  interactions  between  ephrin-A1  and  –A4
expressing astrocytes and retinal fragments with high versus
low  levels  of  Eph-A6  expression  are  required  to  fully
characterize  the  effects  of  Eph-A6  signaling  on  astrocyte
migration. Further investigation of the postnatal expression
profiles  of  Eph–ephrin-As  in  the  dorsal  lateral  geniculate
nucleus, and superior colliculus, will clarify the roles these
factors play in the postnatal refinement of retinal projections
in primates.
ACKNOWLEDGMENTS
We thank Dr. Anita Hendrickson for sourcing macaque tissues
and reading the manuscript, Diyat Sajuthi for expert tissue
preparation,  and  the  staff  at  the  Primate  Centre,  Bogor,
Indonesia  for  their  assistance.  This  work  was  supported
financially by the Australian Research Council through the
ARC Centre of Excellence in Vision Science (CE0561903).
J.P. is an ACEVS chief investigator; P.K. is an ANU Graduate
Scholarship  holder  and  ACEVS  PhD  scholar;  R.N.  is  an
ACEVS research officer; K.B.O. is an ACEVS Fellow.
REFERENCES
1. Dacey DM. The mosaic of midget ganglion cells in the human
retina. J Neurosci 1993; 13:5334-55. [PMID: 8254378]
2. Dacey  DM.  Primate  retina:  cell  types,  circuits  and  color
opponency. Prog Retin Eye Res 1999; 18:737-63. [PMID:
10530750]
3. Provis JM, Penfold PL, Cornish EE, Sandercoe TM, Madigan
MC. Anatomy and development of the macula: specialisation
and  the  vulnerability  to  macular  degeneration.  Clin  Exp
Optom 2005; 88:269-81. [PMID: 16255686]
4. Adams DL, Horton JC. The representation of retinal blood
vessels  in  primate  striate  cortex.  J  Neurosci  2003;
23:5984-97. [PMID: 12853416]
5. Provis JM, Hendrickson AE. The foveal avascular region of
developing human retina. Arch Ophthal 2008; 126:507-11.
[PMID: 18413520]
6. Sandercoe TM, Geller SF, Hendrickson AE, Stone J, Provis JM.
VEGF expression by ganglion cells in central retina before
formation of the foveal depression in monkey retina: evidence
of developmental hypoxia. J Comp Neurol 2003; 462:42-54.
[PMID: 12761823]
7. Stone  J,  Sandercoe  TM,  Provis  JM.  Mechanisms  of  the
formation and stability of retinal blood vessels. In: Tombran-
Tink J, Barnstable C, editors. Ocular Angiogenesis: Diseases,
Mechanisms and Therapeutics. Totowa, NJ: Humana Press;
2005.
8. Engerman RL. Development of the macular circulation. Invest
Ophthalmol 1976; 15:835-40. [PMID: 824224]
9. Provis  JM,  Sandercoe  T,  Hendrickson  AE.  Astrocytes  and
blood vessels define the foveal rim during primate retinal
development. Invest Ophthalmol Vis Sci 2000; 41:2827-36.
[PMID: 10967034]
10. Cheng  H-J,  Nakamoto  M,  Bergemann  AD,  Flanagan  JG.
Complementary gradients in expression and binding of ELF-1
and Mek4 in development of the topographic retinotectal
projection map. Cell 1995; 82:371-81. [PMID: 7634327]
11. Marcus RC, Gale NW, Morrison ME, Mason CA, Yancopoulos
GD.  Eph  family  receptors  and  their  ligands  distribute  in
opposing gradients in the developing mouse retina. Dev Biol
1996; 180:786-9. [PMID: 8954746]
12. Schulte D, Cepko CL. Two homeobox genes define the domain
of  EphA3  expression  in  the  developing  chick  retina.
Development 2000; 127:5033-45. [PMID: 11060230]
13. McLaughlin T, Hindges R, O'Leary DD. Regulation of axial
patterning of the retina and its topographic mapping in the
brain.  Curr  Opin  Neurobiol  2003;  13:57-69.  [PMID:
12593983]
14. Stone J, Dreher Z. Relationship between astrocytes, ganglion
cells and vasculature of the retina. J Comp Neurol 1987;
255:35-49. [PMID: 3819008]
15. Chan-Ling T, Stone J. Factors determining the migration of
astrocytes  into  the  developing  retina:  migration  does  not
Molecular Vision 2009; 15:2649-2662 <http://www.molvis.org/molvis/v15/a282> © 2009 Molecular Vision
2660depend on intact axons or patent vessels. J Comp Neurol 1991;
303:375-86. [PMID: 2007655]
16. Cheng N, Brantley DM, Liu H, Lin Q, Enriquez M, Gale N,
Yancopoulos G, Cerretti DP, Daniel TO, Chen J. Blockade of
EphA receptor tyrosine kinase activation inhibits vascular
endothelial  cell  growth  factor-induced  angiogenesis.  Mol
Cancer Res 2002; 1:2-11. [PMID: 12496364]
17. Steinle JJ, Meininger CJ, Chowdhury U, Wu G, Granger HJ.
Role  of  ephrin  B2  in  human  retinal  endothelial  cell
proliferation  and  migration.  Cell  Signal  2003;  15:1011-7.
[PMID: 14499344]
18. Zamora DO, Davies MH, Planck SR, Rosenbaum JT, Powers
MR. Soluble forms of EphrinB2 and EphB4 reduce retinal
neovascularization in a model of proliferative retinopathy.
Invest  Ophthalmol  Vis  Sci  2005;  46:2175-82.  [PMID:
15914639]
19. Ojima T, Takagi H, Suzuma K, Oh H, Suzuma I, Ohashi H,
Watanabe D, Suganami E, Murakami T, Kurimoto M, Honda
Y,  Yoshimura  N.  EphrinA1  inhibits  vascular  endothelial
growth factor-induced intracellular signaling and suppresses
retinal  neovascularization  and  blood-retinal  barrier
breakdown.  Am  J  Pathol  2006;  168:331-9.  [PMID:
16400034]
20. Kozulin P, Natoli R, O'Brien KM, Madigan MC, Provis JM.
Differential  expression  of  anti-angiogenic  factors  and
guidance genes in the developing macula. Mol Vis 2009;
15:45-59. [PMID: 19145251]
21. Cornish EE, Madigan MC, Natoli R, Hales A, Hendrickson AE,
Provis  JM.  Gradients  of  cone  differentiation  and  FGF
expression during development of the foveal depression in
macaque  retina.  Vis  Neurosci  2005;  22:447-59.  [PMID:
16212702]
22. Lambot M-A, Depasse F, Noel J-C, Vanderhaeghen P. Mapping
labels  in  the  human  developing  visual  system  and  the
evolution of binocular vision. J Neurosci 2005; 25:7232-7.
[PMID: 16079405]
23. Peri S, Navarro JD, Amanchy R, Kristiansen TZ, Jonnalagadda
CK, Surendranath V, Niranjan V, Muthusamy B, Gandhi TK,
Gronborg  M,  Ibarrola  N,  Deshpande  N,  Shanker  K,
Shivashankar  HN,  Rashmi  BP,  Ramya  MA,  Zhao  Z,
Chandrika KN, Padma N, Harsha HC, Yatish AJ, Kavitha
MP,  Menezes  M,  Choudhury  DR,  Suresh  S,  Ghosh  N,
Saravana  R,  Chandran  S,  Krishna  S,  Joy  M,  Anand  SK,
Madavan  V,  Joseph  A,  Wong  GW,  Schiemann  WP,
Constantinescu  SN,  Huang  L,  Khosravi-Far  R,  Steen  H,
Tewari  M,  Ghaffari  S,  Blobe  GC,  Dang  CV,  Garcia  JG,
Pevsner  J,  Jensen  ON,  Roepstorff  P,  Deshpande  KS,
Chinnaiyan  AM,  Hamosh  A,  Chakravarti  A,  Pandey  A.
Development  of  human  protein  reference  database  as  an
initial platform for approaching systems biology in humans.
Genome Res 2003; 13:2363-71. [PMID: 14525934]
24. Mi H, Barres BA. Purification and characterization of astrocyte
precursor cells in the developing rat optic nerve. J Neurosci
1999; 19:1049-61. [PMID: 9920668]
25. Michaelson  IC.  Retinal  Circulation  in  Man  and  Animals.
Springfield IL: Charles C. Thomas; 1954.
26. Ashton N. Retinal angiogenesis in the human embryo. Br Med
Bull 1970; 26:103-6. [PMID: 4911762]
27. Gariano  RF,  Iruela-Arispe  ML,  Hendrickson  AE.  Vascular
development in primate retina: comparison of laminar plexus
formation in monkey and human. Invest Ophthalmol Vis Sci
1994; 35:3442-55. [PMID: 8056520]
28. Gariano  RF,  Kalina  RE,  Hendrickson  AE.  Normal  and
pathological mechanisms in retinal vascular development.
Surv Ophthalmol 1996; 40:481-90. [PMID: 8724640]
29. Provis JM, Leech J, Diaz CM, Penfold PL, Stone J, Keshet E.
Development  of  the  human  retinal  vasculature:  cellular
relations  and  VEGF  expression.  Exp  Eye  Res  1997;
65:555-68. [PMID: 9464188]
30. Gariano RF, Provis JM, Hendrickson AE. Development of the
foveal  avascular  zone.  Ophthalmology  2000;  107:1026.
[PMID: 10857815]
31. Provis JM. Development of the primate retinal vasculature.
Prog Retin Eye Res 2001; 20:799-821. [PMID: 11587918]
32. Garey LJ, de Courten C. Structural development of the lateral
geniculate nucleus and visual cortex in monkey and man.
Behav Brain Res 1983; 10:3-13. [PMID: 6639728]
33. Ciossek T, Monschau B, Kremoser C, Löschinger J, Lang S,
Müller BK, Bonhoeffer F, Drescher U. Eph receptor-ligand
interactions are necessary for guidance of retinal ganglion cell
axons in vitro. Eur J Neurosci 1998; 10:1574-80. [PMID:
9751130]
34. Dütting D, Handwerker C, Drescher U. Topographic targeting
and  pathfinding  errors  of  retinal  axons  following
overexpression of ephrinA ligands on retinal ganglion cell
axons. Dev Biol 1999; 216:297-311. [PMID: 10588880]
35. Vidovic M, Marotte LR, Mark RF. Marsupial retinocollicular
system  shows  differential  expression  of  messenger  RNA
encoding  EphA  receptors  and  their  ligands  during
development.  J  Neurosci  Res  1999;  57:244-54.  [PMID:
10398302]
36. Brown A, Yates PA, Burrola P, Ortuño D, Vaidya A, Jessell
TM, Pfaff SL, O'Leary DD, Lemke G. Topographic mapping
from the retina to the midbrain is controlled by relative but
not absolute levels of EphA receptor signaling. Cell 2000;
102:77-88. [PMID: 10929715]
37. Knöll B, Drescher U. Ephrin-As as receptors in topographic
projections.  Trends  Neurosci  2002;  25:145-9.  [PMID:
11852146]
38. Vidovic M, Marotte LR. Analysis of EphB receptors and their
ligands  in  the  developing  retinocollicular  system  of  the
wallaby reveals dynamic patterns of expression in the retina.
Eur J Neurosci 2003; 18:1549-58. [PMID: 14511334]
39. Pfeiffenberger C, Cutforth T, Woods G, Yamada J, Rentería
RC, Copenhagen DR, Flanagan JG, Feldheim DA. Ephrin-As
and neural activity are required for eye-specific patterning
during  retinogeniculate  mapping.  Nat  Neurosci  2005;
8:1022-7. [PMID: 16025107]
40. Cowan CA, Henkemeyer M. Ephrins in reverse, park and drive.
Trends Cell Biol 2002; 12:339-46. [PMID: 12185851]
41. Brantley-Sieders DM, Chen J. Eph receptor tyrosine kinases in
angiogenesis:  from  development  to  disease.  Angiogenesis
2004; 7:17-28. [PMID: 15302992]
42. Bach H, Feldheim DA, Flanagan JG, Scalia F. Persistence of
graded EphA/Ephrin-A expression in the adult frog visual
system.  J  Comp  Neurol  2003;  467:549-65.  [PMID:
14624488]
43. Rashid T, Upton AL, Blentic A, Ciossek T, Knöll B, Thompson
ID, Drescher U. Opposing gradients of ephrin-As and EphA7
in  the  superior  colliculus  are  essential  for  topographic
Molecular Vision 2009; 15:2649-2662 <http://www.molvis.org/molvis/v15/a282> © 2009 Molecular Vision
2661mapping  in  the  mammalian  visual  system.  Neuron  2005;
47:57-69. [PMID: 15996548]
44. Feldheim DA, Vanderhaeghen P, Hansen MJ, Frisén J, Lu Q,
Barbacid M, Flanagan JG. Topographic guidance labels in a
sensory  projection  to  the  forebrain.  Neuron  1998;
21:1303-13. [PMID: 9883724]
45. Huberman  AD,  Murray  KD,  Warland  DK,  Feldheim  DA,
Chapman  B.  Ephrin-As  mediate  targeting  of  eye-specific
projections to the lateral geniculate nucleus. Nat Neurosci
2005; 8:1013-21. [PMID: 16025110]
46. Gao PP, Zhang JH, Yokoyama M, Racey B, Dreyfus CF, Black
IB, Zhou R. Regulation of topographic projection in the brain:
Elf-1 in the hippocamposeptal system. Proc Natl Acad Sci
USA 1996; 93:11161-6. [PMID: 8855326]
47. Mackarehtschian K, Lau CK, Caras I, McConnell SK. Regional
differences  in  the  developing  cerebral  cortex  revealed  by
ephrin-A5 expression. Cereb Cortex 1999; 9:601-10. [PMID:
10498278]
48. Cang J, Kaneko M, Yamada J, Woods G, Stryker MP, Feldheim
DA. Ephrin-As guide the formation of functional maps in the
visual cortex. Neuron 2005; 48:577-89. [PMID: 16301175]
49. Eglen SJ, Demas J, Wong RO. Mapping by waves. Patterned
spontaneous activity regulates retinotopic map refinement.
Neuron 2003; 40:1053-5. [PMID: 14687538]
50. McLaughlin  T,  Torborg  CL,  Feller  MB,  O'Leary  DD.
Retinotopic  map  refinement  requires  spontaneous  retinal
waves during a brief critical period of development. Neuron
2003; 40:1147-60. [PMID: 14687549]
51. Firth SI, Wang CT, Feller MB. Retinal waves: mechanisms and
function in visual system development. Cell Calcium 2005;
37:425-32. [PMID: 15820390]
52. Adams  RH.  Vascular  patterning  by  Eph  receptor  tyrosine
kinases and ephrins. Semin Cell Dev Biol 2002; 13:55-60.
[PMID: 11969371]
53. Adams  RH,  Wilkinson  GA,  Weiss  C,  Diella  F,  Gale  NW,
Deutsch U, Risau W, Klein R. Roles of ephrinB ligands and
EphB receptors in cardiovascular development: demarcation
of  arterial/venous  domains,  vascular  morphogenesis,  and
sprouting  angiogenesis.  Genes  Dev  1999;  13:295-306.
[PMID: 9990854]
54. Gerety SS, Wang HU, Chen ZF, Anderson DJ. Symmetrical
mutant phenotypes of the receptor EphB4 and its specific
transmembrane  ligand  ephrin-B2  in  cardiovascular
development. Mol Cell 1999; 4:403-14. [PMID: 10518221]
55. Kim I, Ryu YS, Kwak HJ, Ahn SY, Oh JL, Yancopoulos GD,
Gale NW, Koh GY. EphB ligand, ephrinB2, suppresses the
VEGF-  and  angiopoietin  1-induced  Ras/mitogen-activated
protein kinase pathway in venous endothelial cells. FASEB J
2002; 16:1126-8. [PMID: 12039842]
56. McBride  JL,  Ruiz  JC.  Ephrin-A1  is  expressed  at  sites  of
vascular  development  in  the  mouse.  Mech  Dev  1998;
77:201-4. [PMID: 9831653]
57. Pandey A, Shao H, Marks RM, Polverini PJ, Dixit VM. Role of
B61, the ligand for the Eck receptor tyrosine kinase, in TNF-
alpha-induced  angiogenesis.  Science  1995;  268:567-9.
[PMID: 7536959]
58. Zhu M, Provis JM, Penfold PL. The human hyaloid system:
cellular  phenotypes  and  inter-relationships.  Exp  Eye  Res
1999; 68:553-63. [PMID: 10328969]
59. Gariano  RF,  Sage  EH,  Kaplan  HJ,  Hendrickson  AE.
Development of astrocytes and their relation to blood vessels
in  fetal  monkey  retina.  Invest  Ophthalmol  Vis  Sci  1996;
37:2367-75. [PMID: 8933753]
60. Distler C, Kirby MA. Transience of astrocytes in the newborn
macaque  monkey  retina.  Eur  J  Neurosci  1996;  8:847-51.
[PMID: 9081638]
61. Distler  C,  Kopatz  K,  Telkes  I.  Developmental  changes  in
astrocyte density in the macaque perifoveal region. Eur J
Neurosci 2000; 12:1331-41. [PMID: 10762362]
62. Rakic  P.  Prenatal  genesis  of  connections  subserving  ocular
dominance in the rhesus monkey. Nature 1976; 261:467-71.
[PMID: 819835]
63. Donoghue MJ, Rakic P. Molecular gradients and compartments
in the embryonic primate cerebral cortex. Cereb Cortex 1999;
9:586-600. [PMID: 10498277]
64. Hevner RF. Development of connections in the human visual
system  during  fetal  mid-gestation:  a  DiI-tracing  study.  J
Neuropathol  Exp  Neurol  2000;  59:385-92.  [PMID:
10888368]
Molecular Vision 2009; 15:2649-2662 <http://www.molvis.org/molvis/v15/a282> © 2009 Molecular Vision
The print version of this article was created on 4 December 2009. This reflects all typographical corrections and errata to the
article through that date. Details of any changes may be found in the online version of the article.
2662